Unraveling the role of myeloid cells and metabolism in clinical progression of MS

B04

Myeloid cells play an increasingly recognized role in CNS autoimmune conditions such as multiple sclerosis (MS). However, mechanisms that drive disease progression from the relapsing-remitting to the progressive stage and that cause accumulating neurologic damage are far from being definitive. We identified dynamic modes of communication between neurons, CNS-localized myeloid cells and invading T lymphocytes in chronic neuroinflammation. Now, we will link a detailed understanding of the molecular pathways underlying this metabolic communication with a strong translational focus on disease progression. We could demonstrate that enhanced metabolic activity e.g. tissues like tumors or regenerating tissues after injury or during inflammatory processes, promotes an M2-like macrophage phenotype that is orchestrated by the transcription factor ICER in a G protein-coupled receptor (GPCR)- and cAMP-dependent manner (Bohn et al., 2018). We propose that the inflammatory response in the CNS, and accompanying acidification of the tissue, instructs a M2-like tissue repair phenotype in macrophages counteracting neurodegenerative processes and disease progression as an intrinsic defence mechanism of the CNS. To this end, we intend to answer these questions in our working plan:

    1. What is the role of G protein-coupled sensing of acidification and ICER expression in CNS inflammation and disease progression?
    2. What role does the role of ICER in metabolic reprogramming of macrophages and microglia play in CNS inflammation?
    3. What is the role of ICER and GPCR for disease progression in MS patients?


Sekine et al. Nature Immunology, 2018

 

Principal Investigators:

Prof. Dr. med. Stefan Bittner
Department of Neurology, Forschungszentrum Immuntherapie
Mainz
stefan.bittner@unimedizin-mainz.de

Univ.-Prof. Dr. rer. nat. Tobias Bopp
Institut für Immunologie Forschungszentrum Immuntherapie
Mainz
boppt@uni-mainz.de

News

Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more
Fri, 15/01/2021
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
It has long been acknowledged that multiple sclerosis disease risk is associated with reduced sun-exposure, and subsequent low vitamin D levels. The study by Ostkamp et al. now assessed the relationship between measures of sun exposure and MS severity. For this, the researchers analyzed data of around 2,000 patients from the German NationMS- and the […]...more